Osteogenesis Imperfecta and Decreased Bone Density: Sequencing Panel

Test Code: MM173  
Turnaround time: 6 weeks  
CPT Codes: 81404 x1, 81405 x1, 81406 x1

**Condition Description**

Skeletal dysplasias are a heterogeneous group of more than 450 disorders with complex mechanisms. Clinical and biochemical features continue to be used reliably to assign patients to this general disease category. Identification of the precise genetic defect is important, however, to permit carrier testing and early prenatal diagnosis. Molecular analysis is likely to expand the clinical spectrum of skeletal dysplasia and may also provide data relevant to prognosis and future therapeutic intervention.

Collectively, the incidence of skeletal dysplasia is estimated to be 1 in 5,000 births. Skeletal dysplasias with decreased bone density have impaired ossification, fractures, rickets, and/or osteolysis.

References:


**Genes**

ALPL, ANKH, ANOS, ATP6V0A2, B4GALT7, BMP1, CASR, CLCN5, COL1A1, COL1A2, CRTAP, DMP1, ENPP1, FGF23, FKBP10, GNAS, GORAB, IFITM5, LMNA, LRP5, MAFB, MMP2, NOTCH2, P3H1, PHEX, PLOD2, PPIB, PYCR1, SERPINF1, SERPINH1, SLC34A3, SP7, TNFRSF11A, TREM2, TYROBP, ZMPSTE24

**Indications**

This test is indicated for:

- Patients for whom there is a suspicion of skeletal dysplasia with abnormal radiographic findings indicating decreased bone density.

**Methodology**

Next Generation Sequencing: In-solution hybridization of all coding exons is performed on the patient's genomic DNA. Although some deep intronic regions may also be analyzed, this assay is not meant to interrogate most promotor regions, deep intronic regions, or other regulatory elements, and does not detect single or multi-exon deletions or duplications. Direct sequencing of the captured regions is performed using next generation sequencing. The patient's gene sequences are then compared to a standard reference sequence. Potentially causative variants and areas of low coverage are Sanger-sequenced. Sequence variations are classified as pathogenic, likely pathogenic, benign, likely benign, or variants of unknown significance. Variants of unknown significance may require further studies of the patient and/or family members.

**Detection**

Next Generation Sequencing: Clinical Sensitivity: Unknown. Mutations in the promoter region, some mutations in the introns and other regulatory element mutations cannot be detected by this analysis. Large deletions/duplications will not be detected by this analysis. Results of molecular analysis should be interpreted in the context of the patient's clinical/biochemical phenotype.

Analytical Sensitivity: ~99%.

**Specimen Requirements**

Submit only 1 of the following specimen types

**Type: Whole Blood**

Specimen Requirements:

In EDTA (purple top) tube:
- Infants (2 years): 3-5 ml
- Older Children & Adults: 5-10 ml

Specimen Collection and Shipping: Ship sample at room temperature with overnight delivery.

Disclaimer: This information is confidential and subject to change without notice. It may not be reproduced in whole or part unless authorized in writing by an authorized EGL representative.
Type: Isolated DNA

Specimen Requirements:

In microtainer: 60 ug

Isolation using the Qiagen™ Puregene kit for DNA extraction is recommended.

Specimen Collection and Shipping: Refrigerate until time of shipment in 100 ng/ul of TE buffer. Ship sample at room temperature with overnight delivery.

Related Tests

- Comprehensive Skeletal Dysplasia Panel
- Osteogenesis Imperfecta and Decreased Bone Density: Deletion/Duplication Panel